Benzinga · Aug 13, 2026
Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial
Clearmind Medicine advances the CMND-100 clinical trial for alcohol use disorder to Parts B and C following positive Phase A safety data.
CM
NASDAQ · CMND
Clearmind Medicine Inc.
Healthcare · Biotechnology
$1.74
Up+$0.02 (+0.87%)
Updated Aug 24, 2026, 4:27 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 387.88K
- P/E ratio
- -0.07
- Dividend yield
- 0.00%
- 52-week range
- $0.52 – $6.03
- Volume
- 47.14K
- Avg. volume
- 13.42M
Price performance
CMND price history
1M range · 20 trading sessions · Daily adjusted prices
CMND closed at $1.74 after 20 trading sessions, up 7.41% for the selected period.
- Last close
- $1.74
- Period change
- +7.41%
- Period low
- $1.46
- Period high
- $1.96
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $1.74 | $1.835 | $1.74 | $1.74 | 47.14K |
| Aug 20, 2026 | $1.93 | $1.93 | $1.70 | $1.73 | 109.39K |
| Aug 19, 2026 | $1.96 | $1.96 | $1.88 | $1.91 | 63.44K |
| Aug 18, 2026 | $1.88 | $2.31 | $1.84 | $1.96 | 835.58K |
| Aug 17, 2026 | $1.88 | $1.97 | $1.8601 | $1.89 | 45.84K |
| Aug 14, 2026 | $1.88 | $1.8899 | $1.82 | $1.86 | 36.52K |
| Aug 13, 2026 | $1.69 | $1.86 | $1.69 | $1.85 | 207.73K |
| Aug 12, 2026 | $1.61 | $1.67 | $1.60 | $1.65 | 59.88K |
| Aug 11, 2026 | $1.59 | $1.66 | $1.54 | $1.61 | 71.16K |
| Aug 10, 2026 | $1.64 | $1.6699 | $1.58 | $1.60 | 27.08K |
| Aug 7, 2026 | $1.74 | $1.76 | $1.58 | $1.63 | 79.15K |
| Aug 6, 2026 | $1.74 | $1.76 | $1.71 | $1.75 | 69.35K |
| Aug 5, 2026 | $1.68 | $1.80 | $1.68 | $1.76 | 132.65K |
| Aug 4, 2026 | $1.58 | $1.77 | $1.58 | $1.71 | 107.84K |
| Aug 3, 2026 | $1.55 | $1.68 | $1.52 | $1.63 | 374.65K |
| Jul 31, 2026 | $1.63 | $1.705 | $1.60 | $1.69 | 85.03K |
| Jul 30, 2026 | $1.47 | $1.63 | $1.45 | $1.62 | 169.77K |
| Jul 29, 2026 | $1.45 | $1.47 | $1.43 | $1.46 | 40.84K |
| Jul 28, 2026 | $1.56 | $1.56 | $1.43 | $1.46 | 330.11K |
| Jul 27, 2026 | $1.61 | $1.63 | $1.5801 | $1.62 | 40.03K |
Latest CMND news
The latest Smart Investors Daily articles mentioning CMND.
Stock researchCompany · Overview
CMND research
Overview
Company profile and research snapshot.
Company profile
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
ChartMill · Aug 3, 2026
What's going on in today's pre-market session
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Benzinga · Jul 30, 2026
Clearmind Medicine Announces Safety Results From Part A Of Its Ongoing FDA-regulated Phase I/II Clinical Trial Evaluating CMND-100; All 24 Participants Enrolled Across Four Ascending-Dose Cohorts Successfully Completed Treatment
Completed treatment as planned per-protocol, reinforcing the strength of its proprietary drug candidate, CMND-100. The study achieved its primary endpoint of safety and tolerability. CMND-100 demonstrated a consistent
Benzinga · Jul 28, 2026
Clearmind Medicine Completes Treatment For All Participants In Part A Of Its Ongoing Phase I/II Clinical Trial Evaluating CMND-100 For Alcohol Use Disorder
All 24 participants across cohorts 1 through 4 have successfully completed treatment according to the study protocol.The Company is currently assessing the dataset and, assuming results remain favorable, intends to
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
